CCM
CORT icon

CAAS Capital Management’s Corcept Therapeutics CORT Stock Holding History

CAAS Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,892
Closed -$445K – 736
2022
Q4 		$445K Buy
+21,892
New +$549K 0.03% 510
2022
Q1 		– Sell
-95,608
Closed -$1.89M – 711
2021
Q4 		$1.89M Buy
+95,608
New +$1.94M 0.05% 330

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

CAAS Capital Management's CORT Position: Q1 2023 in Review

CAAS Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 21,892 shares — an estimated $445K sold.

CAAS Capital Management first reported a position in CORT in Q4 2021 and held it in 2 quarters. The position peaked at $1.89M in Q4 2021. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

  • CAAS Capital Management reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 21,892 Corcept Therapeutics shares in Q1 2023, an estimated $445K.
  • CAAS Capital Management first reported a position in Corcept Therapeutics in Q4 2021 and held it in 2 quarters.
  • CAAS Capital Management's Corcept Therapeutics position peaked at $1.89M in Q4 2021.
  • 232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.